All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the priority challenges in MDS treatment?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, What are the priority challenges in MDS treatment?

What are the priority challenges in MDS treatment?

Garcia-Manero discusses the priority challenges in MDS treatment, including novel drugs, hypomethylating agent failure, treatments for low-risk MDS, combination therapy, and stem cell transplantation.

 

Share: